A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants

NCT ID: NCT04712006

Last Updated: 2021-09-01

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-30
• Study Completion Date: 2021-10-30

Brief Summary

The purpose of this study is to assess the pharmacokinetic following single subcutaneous administration of Dose 1 or Dose 2 of JNJ-64304500 in healthy Chinese adult participants.

Conditions

Healthy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1: JNJ-64304500

Participants will receive single subcutaneous (SC) Dose 1 of JNJ-64304500 on Day 1.

Group Type: EXPERIMENTAL

JNJ-64304500

Intervention Type: DRUG

Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.

Cohort 2: JNJ-64304500

Participants will receive single SC Dose 2 of JNJ-64304500 on Day 1.

Group Type: EXPERIMENTAL

JNJ-64304500

Intervention Type: DRUG

Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.

Interventions

JNJ-64304500

Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or female Chinese participants whose parents and maternal and paternal grandparents are of Chinese ethnicity
• A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and until Day 113
• A male participant must agree not to donate sperm for the purpose of reproduction and must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and until Day 113
• A woman must have a negative highly sensitive serum beta-human chorionic gonadotropin (hCG) at screening and a negative urine pregnancy test on Day -1 and while enrolled in this study
• Nonsmoker or agree to smoke no more than 10 cigarettes or equivalent of e-cigarettes, or 2 cigars, or 2 pipes of tobacco per day throughout the study, if the inpatient unit allows. However, if smoking is not allowed in the inpatient unit, smokers will not be allowed to smoke while inpatient and cannot use nicotine replacement products during the inpatient period

Exclusion Criteria

• History of any clinically significant medical illness or medical disorders the investigator considers should be exclude the participant, including (but not limited to) liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
• Had major illness or surgery, (example, requiring general anesthesia) within 12 weeks before screening, or will not have fully recovered from illness or surgery, or has surgery planned during the time the participant is expected to participate in the study or until Day 113
• Plans to undergo non-major elective surgery within 4 weeks prior to study intervention administration through the end of the study
• Known or suspected allergies, hypersensitivity or intolerance to JNJ-64304500 or any biologic medication, or known allergies or clinically significant reactions to murine, chimeric, or human proteins, mAbs or antibody fragments, or to any components of the formulation of JNJ-64304500 and its excipients used in this study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Peking University Third Hospital

Beijing, , China

Countries

China

Other Identifiers

64304500CRD1003

Identifier Type: OTHER

Identifier Source: secondary_id

CR108840

Identifier Type: -

Identifier Source: org_study_id